Jim Cramer Explains Why Investors Win With Agios Pharmaceuticals (AGIO)

NEW YORK (TheStreet) -- TheStreet's Jim Cramer notes Agios Pharmaceuticals  (AGIO) has doubled since he started recommending it.

He directs investors to an article in the New Yorker that explains how the company has a novel way of killing cancer in a targeted way by attacking the metabolism of cancer rather than carpet bombing the area. He says it is a unique company and points to positive results from Tuesday night that showed "out-and-out remission" of leukemia.

Cramer says he continues to believe Celgene  (CELG) will buy this $3 billion company if it continues to perform as well as it has, even though he knows the CEO has a desire to build his own franchise. But Cramer says investors win either way. He thinks Agios is still not expensive if this drug works, and it appears to be working now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

AGIO Chart AGIO data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More from Markets

Alphabet Shares Gain as Investors Shrug Off Q1 Google Spending Spree

Alphabet Shares Gain as Investors Shrug Off Q1 Google Spending Spree

SAP Shares Leap After Cloud Business Prompts Full-Year Profit Guidance Hike

SAP Shares Leap After Cloud Business Prompts Full-Year Profit Guidance Hike

Apple Suppliers Slide After European, Asian Chipmakers Echo Smartphone Concerns

Apple Suppliers Slide After European, Asian Chipmakers Echo Smartphone Concerns

Alphabet, Caterpillar, Coca-Cola and Amazon - 5 Things You Must Know

Alphabet, Caterpillar, Coca-Cola and Amazon - 5 Things You Must Know

Global Stocks Edge Higher, But Bond Yields, Oil Prices May Test Market Strength

Global Stocks Edge Higher, But Bond Yields, Oil Prices May Test Market Strength